Silexion advances toward Q2 2026 trial start but faces ongoing cash crisis despite $18M raised

Filed March 17, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 18, 2025 · ~2 min read

Key Changes

• high

  Company submitted regulatory applications in Israel (Q4 2025) and plans Germany submission in Q1 2026, targeting Phase 2/3 trial initiation in Q2 2026. Completed two-species toxicology studies showing no systemic organ toxicity.

  Business: 2025 operational progress verify on EDGAR →
• high

  Despite raising ~$18M through multiple equity offerings in 2025, cash runway is now 'only several months' from March 2026 filing date. Going-concern doubt persists; company under Nasdaq monitoring through September 2026 with no cure period if equity falls below $2.5M.

  MD&A: Liquidity and Nasdaq compliance verify on EDGAR →
• high

  Expanded treatment approach to 'Integrated Treatment Regimen' combining intratumoral and subcutaneous delivery, targeting both localized tumors and micrometastases. Also exploring SIL204-SL for all KRAS mutations (not just G12D/V), broadening addressable population to ~one-third of pancreatic cancer cases.

  Business: Treatment strategy evolution verify on EDGAR →